Strategic Acquisition Following the February 2025 acquisition by Jabil for 20B, Pii has access to expanded global scale, advanced manufacturing capabilities, and broader supply chain resources. This positions Pii to pursue larger, multi-site CDMO opportunities and joint ventures with pharma sponsors seeking integrated development and manufacturing solutions.

Aseptic Expertise Pii specializes in aseptic filling, lyophilization, and high-potency isolation, enabling penetration into sterile injectable and high-potency drug markets. Target opportunities include small to mid-sized biotech and specialty pharma companies developing aseptic products or potent compounds requiring robust containment and quality systems.

IND Readiness Platform The Accelevate Early Development Platform is designed to accelerate IND readiness in about 100 days for aseptic products. This capability can be marketed to sponsors aiming to shorten development timelines, making Pii an attractive partner for expedited early-stage programs and POC-to-IND transitions.

Expansion & Tech Recent investments in prefilled syringe capabilities, automated visual inspection, labeling, and finish technologies signal a robust modernization trajectory. This creates sales opportunities with brands launching self-injectables or complex fill/finish programs that require scalable, compliant manufacturing and end-to-end packaging integration.

Risk & Compliance Significant data breach disclosure in December 2025 highlights elevated cybersecurity and data protection needs. Proactively offering comprehensive data governance, IT security enhancements, and compliant vendor risk management services could differentiate Pii as a trusted partner, appealing to risk-conscious pharmaceutical clients.